TRIUMPH-2 Results: Retatrutide for Obesity with Comorbidities

TRIUMPH-2 addresses the reality that obesity rarely exists in isolation. Most patients with obesity also have hypertension, high cholesterol, elevated triglycerides, or other cardiovascular risk factors. This Phase 3 trial studies retatrutide specifically in patients with these weight-related comorbidities, measuring both weight loss and improvement in the conditions that drive serious health consequences. Phase 2 data showed retatrutide produced 24.2% average weight loss along with significant cardiovascular marker improvements (Jastreboff et al., NEJM 2023).

Why Comorbidities Are the Real Danger

Obesity itself is a chronic disease, but its greatest threat comes from the conditions it causes or worsens. For patients with a BMI of 30+, the most common and dangerous comorbidities include:

• Hypertension: Affects approximately 75% of adults with obesity. A leading cause of heart attack, stroke, and kidney disease.
• Dyslipidemia: Elevated LDL cholesterol and triglycerides occur in the majority of obese patients, accelerating atherosclerosis.
• Cardiovascular disease risk: Obesity doubles the risk of heart failure and significantly increases stroke risk.
• Metabolic syndrome: The cluster of conditions (central obesity, insulin resistance, dyslipidemia, hypertension) that dramatically elevates cardiovascular risk.

TRIUMPH-2 is designed to show that retatrutide does not just reduce weight — it directly improves these dangerous conditions.

Trial Design

What Phase 2 Tells Us to Expect

Phase 2 data included cardiometabolic secondary endpoints that give strong indications of what TRIUMPH-2 may show:

• Blood pressure: Significant reductions in both systolic and diastolic blood pressure were observed across dose groups
• Triglycerides: Meaningful reductions in triglyceride levels
• Cholesterol: Improvements in lipid profiles
• Inflammatory markers: Reductions in C-reactive protein and other inflammatory markers
• Waist circumference: Significant reductions reflecting decreased visceral fat

These improvements tracked closely with the degree of weight loss. With even greater weight loss expected in the longer Phase 3 trial, comorbidity improvements could be even more pronounced.

Clinical Implications

Positive TRIUMPH-2 results would have several important implications:

• Medication reduction: Patients who achieve significant blood pressure and cholesterol reductions may be able to reduce or eliminate blood pressure and statin medications
• Insurance justification: Data showing comorbidity improvement strengthens the case for insurance coverage of retatrutide
• Treatment guidelines: Could position retatrutide as a first-line treatment for obese patients with cardiovascular risk factors
• Quality of life: Reducing the medication burden while improving health markers has significant quality-of-life benefits

Treat Comorbidities with Available Medications Now

Current GLP-1 medications already show significant comorbidity improvements. TRIMI offers:

• Compounded semaglutide: $99/month — proven cardiovascular benefits (SELECT trial)
• Compounded tirzepatide: $125/month — significant cardiometabolic improvements

Learn more about how to get started.